PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 17, 2026 | $4,420,000 | Replaced |
| 1st Quarter - Amendment | Oct 7, 2026 | $4,430,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual Property Protections
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANCISCO CARRILLO | — |
Health Issues HCR
Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANCISCO CARRILLO | — |
| EMILY MUELLER | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Medicare/Medicaid MMM
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| EMILY MUELLER | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Trade (domestic/foreign) TRD
International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHEN CLAEYS | — |
| EMILY MUELLER | — |
| CATHERINE ROBINSON | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.